Denosumab

Denosumab is used to help reduce fracture risk in people with osteoporosis and other bone disorders. This page provides information on the safe use and ongoing management of denosumab treatment.

The prescribing guidance, formularies, pathways and information on this website have transferred from the predecessor organisations that now form NHS Central East ICB.

Guidance may not be available for all clinical topics or geographic areas. Where guidance is available, it is clearly identified as applying to Bedfordshire, Luton and Milton Keynes (BLMK), Cambridgeshire and Peterborough (C&P), Hertfordshire or Central East (CE).

Guidance labelled Central East (CE) has been harmonised and approved for use across NHS Central East ICB. Where CE guidance is not available, local arrangements for BLMK, C&P or Hertfordshire remain in place.

Central East

Denosumab 60mg biosimilar: Patient Information Sheet (docx)

Bedfordshire, Luton and Milton Keynes

Denosumab – Prescribing Support Document (pdf)

Cambridgeshire and Peterborough

Denosumab (Prolia®) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures – Shared Care Guidance (pdf)

Hertfordshire

Prescribing guidelines for people over 50 years with or at risk of osteoporosis (OP) (pdf)

Letter for transfer of care for denosumab biosimilar from specialist to GP (docx)

Prescribing support document for denosumab biosimilar for primary and secondary fracture prevention in osteoporotic men and postmenopausal osteoporotic women (pdf)